Volume 80, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


Despite the growing worldwide burden of dengue fever, the global economic impact of dengue illness is poorly documented. Using a common protocol, we present the first multicountry estimates of the direct and indirect costs of dengue cases in eight American and Asian countries. We conducted prospective studies of the cost of dengue in five countries in the Americas (Brazil, El Salvador, Guatemala, Panama, and Venezuela) and three countries in Asia (Cambodia, Malaysia, and Thailand). All studies followed the same core protocol with interviews and medical record reviews. The study populations were patients treated in ambulatory and hospital settings with a clinical diagnosis of dengue. Most studies were performed in 2005. Costs are in 2005 international dollars (I$). We studied 1,695 patients (48% pediatric and 52% adult); none died. The average illness lasted 11.9 days for ambulatory patients and 11.0 days for hospitalized patients. Among hospitalized patients, students lost 5.6 days of school, whereas those working lost 9.9 work days per average dengue episode. Overall mean costs were I$514 and I$1,394 for an ambulatory and hospitalized case, respectively. With an annual average of 574,000 cases reported, the aggregate annual economic cost of dengue for the eight study countries is at least I$587 million. Preliminary adjustment for under-reporting could raise this total to $1.8 billion, and incorporating costs of dengue surveillance and vector control would raise the amount further. Dengue imposes substantial costs on both the health sector and the overall economy.


Article metrics loading...

Loading full text...

Full text loading...



  1. World Health Organization (WHO). Dengue and dengue haemorrhagic fever. Fact sheet N°117. Available at: http://www.who.int/mediacentre/factsheets/fs117/en/print.html. Accessed September 26, 2006.
  2. World Tourism Organization. Tourism highlights. Available at: www.world-tourism.org/facts/menu.html. Accessed September 26, 2007.
  3. Economic Research Institute. Human resources tax codes and laws. Available at: http://www.erieri.co.uk/freedata/HRCodes/. Accessed January 31, 2007.
  4. International Labour Organization. Minimum wages database. Available at: http://www.ilo.org/travaildatabase/servlet/mini-mumwages. Accessed January 30, 2007.
  5. Akomsoonthorn A, Simakulthorn S. Thailand: minimum wage increase. Available at: http://www.jsm.com.hk/live/Portal?xml=legal_update/article&content_id=2120. Accessed January 30, 2007.
  6. Suaya JA, Shepard DS, Beatty ME, Dengue Burden of Disease and Cost of Illness. Scientific Working Group: Report on Dengue (Vol. TDR/SWG/08), Geneva: World Health Organization on behalf of the Special Programme for Research and Training in Tropical Diseases; 2007:TDR/SWG/08.
  7. Shepard DS, Suaya JA, Halstead SB, Nathan MB, Gubler DJ, Mahoney RT, Wang, DN, Meltzer MI, 2004. Cost-effectiveness of a pediatric dengue vaccine. Vaccine 22 : 1275–1280.
  8. Suaya JA, Shepard DS, Chang MS, Caram M, Hoyer S, Socheat D, Chantha N, Nathan MB, 2007. Cost-effectiveness of annual targeted larviciding campaigns in Cambodia against the dengue vector Aedes aegypti. Journal of Tropical Medicine and International Health 12 : 1026–1036.
  9. Rice DP, Estimating the Cost-of-Illness. Washington, DC: US Department of Health, Education, and Welfare, Public Health Service; 1966.
  10. Okanurak K, Sornmani S, Indaratna K, 1997. The cost of dengue hemorrhagic fever in Thailand. Southeast Asian J Trop Med Public Health 28 : 711–717.
  11. Meltzer MI, Rigau-Pérez JG, Clark GG, Reiter P, Gubler DJ, 1998. Using disability-adjusted life years to assess the economic impact of dengue in Puerto Rico: 1984–1994. Am J Trop Med Hyg 59 : 265–271.
  12. Torres M, 1997. Impact of an outbreak of dengue fever: a case study from rural Puerto Rico. Hum Organ 56 : 19–27.
  13. Valdés LG, Mizhrahi JV, Guzmán MG, 2002. Impacto económico de la epidemia de dengue 2 en Santiago de Cuba, 1997. Rev Cubana Med Trop 54 : 220–227.
  14. Clark DV, Mammen MP Jr, Nisalak A, Puthimethee V, Endy TP, 2005. Economic impact of dengue fever/dengue hemorrhagic fever in Thailand at the family and population levels. Am J Trop Med Hyg 72 : 786–791.
  15. Añez G, Balza R, Valero N, Larreal Y, 2006. Impacto económico del dengue y del dengue hemorrágico en el Estado de Zulia, Venezuela, 1997–2003. Rev Panam Salud Publica 19 : 314–320.
  16. Anderson KB, Chunsuttiwat S, Nisalak A, Mammen MP, Libraty DH, Rothman AL, Green S, Vaughn DW, Ennis FA, Endy TP, 2007. Burden of symptomatic dengue infection in children at primary school in Thailand: a prospective study. Lancet 369 : 1452–1459.
  17. Harving ML, Ronsholt FF, 2007. The economic impact of dengue hemorrhagic fever on family level in Southern Vietnam. Dan Med Bull 54 : 170–172.
  18. Shepard DS, Halstead SB, Dengue (with notes on yellow fever and Japanese encephalitis). Jamison DT, Mosley WH, Measham AR, Bobadilla JL, eds. Disease Control Priorities for Developing Countries. New York: Oxford University Press for the World Bank, 1993, 303–320.
  19. Halstead SB, Suaya JA, Shepard DS, 2007. The burden of dengue infection. Editorial comment. Lancet 369 : 1410–1411.
  20. World Health Organization (WHO), Dengue Haemorrhagic Fever: Diagnosis, Treatment, Prevention and Control. Second edition. Geneva: WHO, 1997.
  21. Pan American Health Organization (PAHO), World Health Organization (WHO), 2000. Case definitions: dengue and leptospirosis. Epidemiol Bull 21. Available at: http://www.paho.org/English/sha/be_v21n2-cases.htm. Accessed September 26, 2007.
  22. South-East Asia Regional Office (SEARO), World Health Organization (WHO). Management of Dengue Epidemic (SEA/DEN/1). Annex 8: Clinical Case Definition for Dengue Haemorrhagic Fever (SEA/DEN/1). Available at: http://www.searo.who.int/en/Section10/Section332/Section366_1153.htm. Accessed October 3, 2007.
  23. Shepard DS, Hodgkin D, Anthony Y, 2000. Analysis of Hospital Costs: A Manual for Managers. Geneva, Switzerland: World Health Organization.
  24. Adam T, Evans DB, Murray CJ, 2003. Econometric estimation of country-specific hospital costs. Cost Eff Resour Alloc 1 : 3.
  25. Iunes R, Campino ACC, Prottas J, Shepard DS, 1998. Expenditures on HIV/AIDS in the State of São Paulo, Brazil. Ainsworth M, Fransen L, Over M, eds. Confronting AIDS: Evidence from the Developing World. Brussels: European Commission, 273–287.
  26. Ministério da Saúde, Brasil. Instituto de Pesquisa Econômica Aplicada (IPEA). Atenção de alta complexidade no SUS: desigualdades no acesso e no financiamento: Brasilia Ministério da Saúde, Brasilia, 2005.
  27. Shogren J, 2001. Children and the environment: valuing indirect effects on a child’s life chances. Contemp Econ Policy 19 : 382–396.
  28. Hall J, Brajer V, Lurmann F, 2003. Economic valuation of ozone-related school absences in the South Coast Air Basin of California. Contemp Econ Policy 21 : 407–417.
  29. The World Bank Group, EDSTATS. Available at: http://devdata.worldbank.org/edstats/cd1.asp. Accessed January 31, 2007.
  30. Glied S, 1996. Estimating the indirect cost-of-illness: an assessment of the forgone earnings approach. Am J Public Health 86 : 1723–1728.
  31. World Health Organization (WHO). Purchasing power parity. Choosing interventions that are cost effective (WHO-CHOICE). Available at: http://www.who.int/choice/costs/ppp/en/print.html. Accessed November 18, 2008.
  32. SPSS, 2006. Version 14 for Windows: SPSS Inc., Chicago, IL.
  33. World Health Organization (WHO). WHO-CHOICE. Available at: http://www.who.int/choice/en. Accessed January 20, 2008.
  34. World Health Organization (WHO). Life tables for WHO member states for year 2005. Available at: http://www.who.int/whosis/database/life_tables/life_tables.cfm. Accessed Jamuary 15, 2008.
  35. Shepard DS, Zeckhauser RJ, 1984. Survival versus consumption. Manage Sci 30 : 423–439.
  36. Pauly MV, Nicholson S, Xu J, Polsky D, Danzon PM, Murray JF, Berger ML, 2002. A general model of the impact of absenteeism on employers and employees. Health Econ 11 : 221–231.
  37. Drummond M, O’Brien B, 1993. Clinical importance, statistical significance and the assessment of economic and quality-of-life outcomes. Health Econ 2 : 205–212.
  38. Crystal Ball, 2008. Version 7.3: Oracle USA, Inc., Redwood City, CA.
  39. Microsoft Office, 2003. Excel: Microsoft Corporation, Seattle, WA.
  40. Beaston-Blaakman A, Shepard DS, Stone N, Shevitz AH, 2007. Cost-effectiveness of clinical interventions for AIDS wasting. AIDS Care 19 : 996–1001.
  41. World Health Organization (WHO), Regional Office for SouthEast Asia (SEARO). Dengue and dengue hemorrhagic fever: clinical diagnosis and management of dengue epidemic, 2007 (December 17, 2007).
  42. Halstead SB, 1988. Pathogenesis of dengue: challenges to molecular biology. Science 239 : 476–481.
  43. Halstead SB, 2003. Neutralization and antibody dependent enhancement of dengue viruses. Adv Virus Res 60 : 421–467.
  44. Watts DM, Porter K, Putvatana R, Vasquez B, Calampa C, Hayes CG, Halstead SB, 1999. Failure of secondary infections with American genotype dengue 2 viruses to cause dengue haemorrhagic fever. Lancet 354 : 1431–1434.
  45. Guzman MG, Kouri G, Valdes L, Bravo J, Alvarez M, Vazques S, Delgardo I, Halstead SB, 2000. Epidemiologic studies on dengue, Santiago de Cuba. Am J Epidemiol 152 : 793–799.
  46. Gibbons RV, Kalanarooj S, Jarman RG, Nisalak A, Vaughn DW, Endy TP, Mammen MP Jr, Srikiatkhachorn A, 2007. Analysis of repeat hospital admissions for dengue to estimate the frequency of third and fourth resulting in admissions and dengue hemorrhagic fever, and serotype sequences. Am J Trop Med Hyg 77 : 910–913.
  47. Rattanadilok Na Bhuket T, Nawanoparatkul S, Suwanjutha S, 2002. Economic burden in management of acute lower respiratory infection, patients’ perspective: a case study of Takhli District Hospital. J Med Assoc Thai 85 (Suppl 4): S1241–S1245.
  48. Dayan GH, Nguyen VH, Debbag R, 2001. Cost-effectiveness of influenza vaccination in high-risk children in Argentina. Vaccine 19 : 4204–4213.
  49. Isakbaeva ET, Musabaev E, Antil L, Rheingans R, Jurgev R, Glass RI, Bresee JS, 2007. Rotavirus disease in Uzbekistan: cost-effectiveness of a new vaccine. Vaccine 25 : 373–380.
  50. Guzmán A, Hoz N, 2005. The economic costs of pneumonia in children under 2 years of age in Colombia. Pan American Journal of Public Health. 17 : 178–183.
  51. Bahl R, Sinha A, Poulos C, Whittington D, Sazawai S, Kumar R, Mahalanabis D, Acosta CJ, Clemens JD, Bhan MK, 2004. Costs of illness due to typhoid fever in an Indian urban slum community: implications for vaccination policy. J Health Popul Nutr 22 : 304–310.
  52. World Health Organization (WHO), 2006. Cost effectiveness of rotavirus vaccines and other interventions for diarrhoeal diseases: meeting report 2006. Wkly Epidemiol Rec 81 : 349–356 (WER).
  53. Halstead SB, 2006. Dengue in the Americas and Southeast Asia: do they differ? Rev Panam Salud Publica 20 : 407–415.
  54. Duarte HH, Franca EB, 2006. Data quality of dengue epidemio-logical surveillance in Belo Horizonte, Southeastern Brazil. Rev Saude Publica 40 : 134–142.
  55. Rigau-Pérez JG, 1999. Surveillance for an emerging disease: dengue hemorrhagic fever in Puerto Rico, 1988–1997. Puerto Rico Association of Epidemiologists. PR Health Sci J 18 : 337–345.
  56. Armien B, Suaya JA, Quiroz E, Sah BK, Bayard V, Marchena L, Campos C, Shepard DS, 2008. Clinical characteristics and national economic cost of the 2005 dengue epidemic in Panama. Am J Trop Med Hyg 79 : 364–371.
  57. Pan American Health Organization (PAHO), Communicable Diseases Program Division of Disease Prevention and Control, 1999. A blueprint for action for the next generation: dengue prevention and control. PAHO/HCP/HCT/136/99. Washington, DC.

Data & Media loading...

  • Received : 22 Sep 2008
  • Accepted : 13 Jan 2009

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error